HIV and the Immune Disorder Listings Today

The Social Security Administration evaluates HIV infection under Blue Book Listing 14.11, not 14.08. The current Blue Book marks Listing 14.08 as reserved, and older sources that still describe 14.08 criteria are out of date, a point worth knowing because the renumbered listing changed how claims are actually decided. In the modern antiretroviral era, approval usually rests on resistant infections, repeated hospitalizations, treatment side effects, and measurable functional decline rather than on a diagnosis alone.

Section 14.00F1 of the Blue Book sets the documentation threshold. HIV infection can be established by laboratory evidence such as an antibody screening test confirmed by a supplemental test like a Western blot or an HIV-1/HIV-2 differentiation assay, a nucleic acid detection test such as PCR, a p24 antigen test, or viral culture. SSA can also accept a persuasive physician report of a confirmed positive test, or a diagnosis supported by medical history and clinical findings when an opportunistic disease predictive of a cell-mediated immune defect, such as toxoplasmosis of the brain or Pneumocystis pneumonia, is present with no other known cause.

The Opportunistic Disease Criteria in 14.11A Through 14.11E

The first five criteria cover conditions that SSA treats as inherently listing-level when documented in a person with HIV. Each has its own documentation standard in Section 14.00F3.

Criterion 14.11A covers multicentric Castleman disease affecting multiple groups of lymph nodes, and requires characteristic findings on microscopic examination of biopsied lymph nodes. Criterion 14.11B covers primary central nervous system lymphoma, documented by microscopic examination of cerebrospinal fluid or biopsied brain tissue. Criterion 14.11C covers primary effusion lymphoma, documented by examination of effusion fluid or biopsied tissue. Section 7.00A2 of the Blue Book confirms that these two HIV-associated lymphomas are evaluated under 14.11B and 14.11C rather than under the cancer listings in 13.00.

Criterion 14.11D covers progressive multifocal leukoencephalopathy, a degenerative brain syndrome caused by the JC virus, documented by clinical findings, characteristic white matter lesions on MRI, and a positive PCR test for JC virus in cerebrospinal fluid. Criterion 14.11E covers pulmonary Kaposi sarcoma, the most serious form of that cancer, documented by examination of induced sputum, bronchoalveolar lavage washings, or biopsied transbronchial tissue.

All five of these conditions also appear on SSA's Compassionate Allowances list, which flags claims for expedited handling. HIV infection as such is not a Compassionate Allowance condition, so claims resting on hospitalizations or functional decline proceed through standard development.

Laboratory Severity: The CD4 Criteria in 14.11F and 14.11G

Two criteria convert immune measurement into listing-level severity. Criterion 14.11F requires a single absolute CD4 count of 50 cells/mm3 or less, measured within the period SSA is considering, and Section 14.00F4 states that when more than one measurement exists, SSA uses the lowest.

Criterion 14.11G is broader. It requires an absolute CD4 count below 200 cells/mm3 or a CD4 percentage below 14 percent, combined with either a body mass index under 18.5 or a hemoglobin under 8.0 grams per deciliter (g/dL). The values do not need to be measured on the same date, and Section 14.00F5 instructs SSA to use the lowest CD4, BMI, and hemoglobin values in the period, calculating BMI under the digestive formulas in 5.00F.

Hospitalizations: Criterion 14.11H

Hospital-based care drives many modern HIV claims. Criterion 14.11H requires complications of HIV infection resulting in at least three hospitalizations within a 12-month period, occurring at least 30 days apart, with each hospitalization lasting at least 48 hours. Section 14.00F6 states that hours in a hospital emergency department immediately before the admission count toward the 48 hours.

Qualifying complications are not limited to a fixed list, and Section 14.00F6a gives examples that include depression, diarrhea, immune reconstitution inflammatory syndrome, malnutrition, and Pneumocystis pneumonia and other severe infections. The hospitalizations may be for the same complication or different ones. Section 14.00F6c adds that SSA uses medical equivalence principles under 20 CFR 404.1526 for people with fewer but longer hospitalizations, or more frequent but shorter ones, or care in alternative settings such as nursing or rehabilitation facilities.

Functional Decline: Criterion 14.11I

The final criterion, 14.11I, is the one most people with treated HIV actually rely on. It covers repeated manifestations of HIV infection, including conditions that fall short of criteria A through H, for example Kaposi sarcoma that does not meet 14.11E, or other manifestations such as cardiovascular disease, distal sensory polyneuropathy, glucose intolerance, hepatitis, HIV-associated dementia, infections, lipodystrophy, malnutrition, myositis, pancreatitis, or peripheral neuropathy. These must result in significant documented symptoms or signs, such as fever, headaches, insomnia, involuntary weight loss, malaise, nausea, night sweats, pain, severe fatigue, or vomiting.

The claimant must also show a marked limitation in one of three areas: activities of daily living, maintaining social functioning, or completing tasks in a timely manner due to deficiencies in concentration, persistence, or pace. Section 14.00I3 defines repeated as manifestations occurring on average three times a year, or once every 4 months, each lasting 2 weeks or more, with alternatives for shorter but more frequent, or rarer but longer, episodes. Section 14.00F7 specifically reminds adjudicators to consider gynecologic problems and other manifestations common in women with HIV when applying these rules.

Treatment Effects in the Antiretroviral Era

Section 14.00G is where the modern treatment reality enters the analysis. SSA must consider the effectiveness of treatment, its side effects, its intrusiveness, and the variability of your response. For HIV specifically, Section 14.00G5 lists side effects of antiretroviral drugs that include bone marrow suppression, pancreatitis, gastrointestinal intolerance, neuropathy, rash, hepatotoxicity, lipodystrophy, glucose intolerance, and lactic acidosis, along with effects on concentration, memory, and mood. The section notes that symptoms of HIV and side effects of medication may be indistinguishable, and that SSA considers all functional limitations from either source.

Structured treatment interruptions, sometimes called drug holidays, do not count against you when prescribed by a treating source. Section 14.00G6 addresses people who have not received ongoing treatment, directing SSA to evaluate severity from the current objective evidence, with the possibility of allowing a claim later once the effect of treatment becomes clear.

If No Listing Is Met

Under Section 14.00J, SSA then considers listings in other body systems, medical equivalence under 20 CFR 404.1526, and residual functional capacity at the later steps of the sequential evaluation in 20 CFR 404.1520. HIV can accelerate conditions such as cardiovascular disease and hepatitis, and each is evaluated under its own body system. Non-medical rules also apply: in 2026 a work credit is earned for each $1,890 in covered wages, most adults need 20 credits in the 10 years before onset, and substantial gainful activity is capped at $1,690 in average monthly earnings, or $2,830 for statutorily blind claimants. Filing mechanics and appeals are covered by separate rules outside this article's scope.

Frequently Asked Questions

Is HIV still evaluated under Listing 14.08? No. The current Blue Book marks 14.08 as reserved, and SSA evaluates HIV infection under Listing 14.11, which contains the criteria for opportunistic diseases, CD4 measurements, hospitalizations, and functional limitations.

What CD4 count meets Listing 14.11? An absolute CD4 count of 50 cells/mm3 or less meets the listing by itself under criterion 14.11F. A count below 200 cells/mm3, or a CD4 percentage below 14 percent, also qualifies when paired with a BMI under 18.5 or hemoglobin under 8.0 g/dL.

Can side effects of antiretroviral drugs support a claim? Yes. Section 14.00G5 directs SSA to consider side effects such as neuropathy, lipodystrophy, pancreatitis, and cognitive changes, together with symptoms of HIV itself, when assessing functioning.

This article provides general information about SSDI eligibility for HIV infection, not legal advice. Program rules, medical listings, and dollar thresholds change over time, and all figures cited here reflect federal standards in effect in 2026. Consult a qualified representative or contact the Social Security Administration directly about your specific claim.